Gwang-Cheol Park
Director Ejecutivo en Premierbio Co., Ltd. .
Perfil
Gwang-Cheol Park is currently the Chief Executive Officer at Premierbio Co., Ltd.
Prior to this, he was the Chairman & Co-Chief Executive Officer at DSK Co., Ltd.
and an Independent Director at KB Securities Co., Ltd.
He received his undergraduate, graduate, and doctorate degrees from Konkuk University.
Cargos activos de Gwang-Cheol Park
| Empresas | Cargo | Inicio |
|---|---|---|
Premierbio Co., Ltd.
 Premierbio Co., Ltd. Pharmaceuticals: OtherHealth Technology Premierbio Co., Ltd. is engaged in developing Protoxin. It offers development and supply of Botulinum type A Toxin. The company was founded on September 25, 2015 and is headquartered in Anseong, South Korea. | Director Ejecutivo | - |
Antiguos cargos conocidos de Gwang-Cheol Park.
| Empresas | Cargo | Fin |
|---|---|---|
| DSK CO., LTD. | Director Ejecutivo | - |
| HYUNDAI SECURITIES CO LTD | Director/Miembro de la Junta | - |
Formación de Gwang-Cheol Park.
| Konkuk University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| DSK CO., LTD. | Electronic Technology |
| Empresas privadas | 2 |
|---|---|
KB Securities Co., Ltd
 KB Securities Co., Ltd Investment ManagersFinance KB Securities Co., Ltd (KB Securities) is a private equity subsidiary of KB Financial Group, Inc. founded in 1962. The firm is headquartered in Seoul, South Korea. | Finance |
Premierbio Co., Ltd.
Premierbio Co., Ltd. Pharmaceuticals: OtherHealth Technology Premierbio Co., Ltd. is engaged in developing Protoxin. It offers development and supply of Botulinum type A Toxin. The company was founded on September 25, 2015 and is headquartered in Anseong, South Korea. | Health Technology |
- Bolsa de valores
- Insiders
- Gwang-Cheol Park
